P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of $^{11}$C-metoclopramide across the blood-brain barrier: a PET study on non-human primates

Archive ouverte

Auvity, Sylvain | Caillé, Fabien | Marie, Solène | Wimberley, Catriona | Bauer, Martin | Langer, Oliver | Buvat, Irène | Goutal, Sébastien | Tournier, Nicolas

Edité par CCSD ; Society of Nuclear Medicine -

International audience. Rationale: PET imaging using radiolabeled high-affinity substrates of P-glycoprotein (ABCB1) has convincingly revealed the role of this major efflux transporter in limiting the influx of its substrates from blood into the brain across the blood-brain barrier (BBB). Many drugs, such as metoclopramide, are weak ABCB1 substrates and distribute into the brain even when ABCB1 is fully functional. In this study, we used kinetic modeling and validated simplified methods to highlight and quantify the impact of ABCB1 on the BBB influx and efflux of $^{11}$C-metoclopramide, as a model weak ABCB1 substrate, in non-human primates. Methods: The regional brain kinetics of a tracer dose of $^{11}$C-metoclopramide (298 ± 44 MBq) were assessed in baboons using PET without (n = 4) or with intravenous co-infusion of the ABCB1 inhibitor tariquidar (4 mg/kg/h, n = 4). Metabolite-corrected arterial input functions were generated to estimate the regional volume of distribution (V$_T$) as well as the influx (K$_1$) and efflux (k$_2$) rate constants, using a one-tissue compartment model. Modeling outcome parameters were correlated with image-derived parameters, i.e. area under the curve AUC$_{0-30}$$_{min}$ and AUC$_{30-60min}$ (SUV.min) as well as the elimination slope (k$_E$; min$^{-1}$) from 30 to 60 min of the regional time-activity curves. Results: Tariquidar significantly increased the brain distribution of $^{11}$C-metoclopramide (V$_T$ = 4.3 ± 0.5 mL/cm$^3$ and 8.7 ± 0.5 mL/cm$^3$ for baseline and ABCB1 inhibition conditions, respectively, P<0.001), with a 1.28-fold increase in K$_1$ (P < 0.05) and a 1.64-fold decrease in k$_2$ (P < 0.001). The effect of tariquidar was homogeneous across different brain regions. The most sensitive parameters to ABCB1 inhibition were V$_T$ (2.02-fold increase) and AUC$_{30-60min}$ (2.02-fold increase). V$_T$ was significantly (P < 0.0001) correlated with AUC$_{30-60min}$ (r$^2$ = 0.95), AUC$_{0-30min}$ (r$^2$ = 0.87) and kE (r$^2$ = 0.62). Conclusion: $^{11}$C-metoclopramide PET imaging revealed the relative importance of both the influx hindrance and efflux enhancement components of ABCB1 in a relevant model of the human BBB. The overall impact of ABCB1 on drug delivery to the brain can be non-invasively estimated from image-derived outcome parameters without the need for an arterial input function.

Consulter en ligne

Suggestions

Du même auteur

Parametric Imaging of P-Glycoprotein Function at the Blood–Brain Barrier Using kE,brain-maps Generated from [11C]Metoclopramide PET Data in Rats, Nonhuman Primates and Humans

Archive ouverte | Breuil, Louise | CCSD

International audience

Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?

Archive ouverte | Breuil, Louise | CCSD

International audience. Only partial deficiency/inhibition of P-glycoprotein (P-gp, ABCB1) function at the blood-brain barrier (BBB) is likely to occur in pathophysiological situations or drug-drug interactions. Thi...

Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood–Brain Barrier: A PET Study on Nonhuman Primates

Archive ouverte | Tournier, Nicolas | CCSD

International audience. The tyrosine kinase inhibitor erlotinib poorly penetrates the blood-brain barrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), the...

Chargement des enrichissements...